Juno Therapeutics, Inc. (NASDAQ:JUNO) was upgraded by investment analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $45.00 target price on the biopharmaceutical company’s stock. Raymond James Financial, Inc.’s price objective suggests a potential upside of 23.36% from the stock’s current price.

Several other analysts have also recently weighed in on JUNO. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research report on Tuesday, May 23rd. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research report on Tuesday, July 11th. Morgan Stanley lowered their price objective on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Monday, May 8th. Finally, FBR & Co restated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.48.

Shares of Juno Therapeutics (JUNO) traded up 17.87% during trading on Tuesday, reaching $43.00. The company had a trading volume of 7,241,134 shares. The firm has a 50 day moving average price of $28.62 and a 200 day moving average price of $25.14. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $43.74. The company’s market cap is $4.51 billion.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the prior year, the company earned ($0.64) earnings per share. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. Analysts predict that Juno Therapeutics will post ($3.13) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Lifted to Outperform at Raymond James Financial, Inc.” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/29/juno-therapeutics-inc-juno-stock-rating-upgraded-by-raymond-james-financial-inc.html.

In other Juno Therapeutics news, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the sale, the director now owns 788,985 shares of the company’s stock, valued at approximately $23,937,804.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Anthony B. Evnin purchased 9,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was purchased at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the acquisition, the director now owns 66,301 shares in the company, valued at $1,617,744.40. The disclosure for this purchase can be found here. In the last three months, insiders sold 8,053,500 shares of company stock worth $217,594,440. Insiders own 15.26% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Broadfin Capital LLC boosted its stake in Juno Therapeutics by 49.2% in the second quarter. Broadfin Capital LLC now owns 262,100 shares of the biopharmaceutical company’s stock valued at $7,834,000 after buying an additional 86,400 shares in the last quarter. Wasatch Advisors Inc. bought a new stake in Juno Therapeutics during the second quarter valued at approximately $19,787,000. Public Employees Retirement System of Ohio boosted its stake in Juno Therapeutics by 115.3% in the second quarter. Public Employees Retirement System of Ohio now owns 56,326 shares of the biopharmaceutical company’s stock valued at $1,684,000 after buying an additional 30,170 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Juno Therapeutics by 809,500.0% in the second quarter. Tower Research Capital LLC TRC now owns 16,192 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 16,190 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares in the last quarter. 70.76% of the stock is owned by hedge funds and other institutional investors.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.